New Cancer Drugs Show Promising Results in Improving Survival and Reducing Disease Progression.

ImmunoGen's ELAHERE has demonstrated a 35% reduction in the risk of disease progression or death compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC), according to results from the Phase 3 confirmatory MIRASOL trial. ELAHERE is the first treatment to show an overall survival benefit in this patient population. The data further support the potential of ELAHERE to become the new standard of care for patients with FRα-positive platinum-resistant ovarian cancer.